8kbody
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
---------------------------------------------------------------------------------------------------------------------------------------
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
August 16, 2002
Commission File No. 0-19131
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
Delaware 52-1555759
(State or other jurisdiction of (I. R. S. Employer
incorporation or organization) Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
ITEM 9. Regulation FD Disclosure
The registrant hereby incorporates by reference the press release dated
August 15, 2002 attached hereto as Exhibit 99.1 ("MedImmune Licenses Rights to Newly Discovered Human Metapneumovirus").
ITEM 7. Financial Statements, ProForma Information and Exhibits
(c) Exhibits.
Exhibit
Number Description
------ -----------
99.1 Press Release - MedImmune Licenses Rights to Newly Discovered Human Metapneumovirus
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
MEDIMMUNE, INC.
(Registrant)
/s/: Gregory S. Patrick
Date: August 16, 2002 Gregory S. Patrick
Senior Vice President and Chief Financial Officer